The $15 "Insider Secret" That Could Save Your Retirement

What if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.

Click here to discover the name and ticker of this "$15 billionaire-backed retirement stock" >>>

Elvia Cowan Biography and Net Worth

SVP of Vaxcyte

Elvia Cowan is currently working as Vice President & Controller at 23andMe, Inc. and Senior Vice President-Finance at Vaxcyte, Inc. She previously worked as Director-Collaborations Management at Gilead Sciences, Inc., Director-Global Consolidations at Levi Strauss & Co., International Controller at The PMI Group, Inc., Controller at Tecan Genomics, Inc., Assurance Manager at KPMG LLP, Vice President-Finance at Stella & Dot LLC, Chief Financial Officer at Ruby Ribbon, Inc., and Vice President & Controller at 23andMe Holding Co. She completed her undergraduate degree from Mount St. Mary's University, Inc.

What is Elvia Cowan's net worth?: The estimated net worth of Elvia Cowan is at least $1.42 million as of September 3rd, 2024. Ms. Cowan owns 12,723 shares of Vaxcyte stock worth more than $1,419,632 as of September 7th. This net worth evaluation does not reflect any other assets that Ms. Cowan may own. Learn More about Elvia Cowan's net worth.
How old is Elvia Cowan?: Ms. Cowan is currently 51 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on Elvia Cowan's age.
How do I contact Elvia Cowan?: The corporate mailing address for Ms. Cowan and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Elvia Cowan's contact information.
Has Elvia Cowan been buying or selling shares of Vaxcyte?: Within the last three months, Elvia Cowan has sold $1,363,350.00 in Vaxcyte stock. Most recently, Elvia Cowan sold 5,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a transaction totalling $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares of the company's stock, valued at $1,369,885.41. Learn More on Elvia Cowan's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 49 times. They sold a total of 411,862 shares worth more than $27,439,668.67. The most recent insider tranaction occured on September, 3rd when COO Jim Wassil sold 10,000 shares worth more than $1,119,300.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 9/3/2024.

Elvia Cowan Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/3/2024	Sell	5,000	$107.67	$538,350.00	12,723
7/16/2024	Sell	5,000	$85.00	$425,000.00	12,723
7/8/2024	Sell	5,000	$80.00	$400,000.00	12,723
3/1/2024	Sell	11,678	$74.08	$865,106.24	12,480

Elvia Cowan Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $111.58

$110.48

$115.44

50 Day Range

MA: $81.80

$70.52

$112.10

2 Week Range

Now: $111.58

$44.20

$119.27

Volume

2,346,199 shs

Average Volume

833,799 shs

Market Capitalization

$12.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

The $15 "Insider Secret" That Could Save Your Retirement

From Behind the Markets | Ad